Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Interferon Beta1b

Research Leaders

10 sponsors active, led by Hospital Authority, Hong Kong

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT04610515Completed

Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)

NCT04276688Phase 2CompletedPrimary

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

Showing all 2 trials

Research Network

Common Treatments

  • Interferon Beta1b1
  • Lopinavirritonavir1
  • Ribavirin1

Active Sponsors

  • Hospital Authority, Hong Kong1
  • The University of Texas Health Science Center, Houston1
  • University of Washington1
  • University of California, San Francisco1
  • University of Texas Southwestern Medical Center1

Top Investigators

Related Conditions

  • Mecfs1
  • Sars Cov21
  • Cardiovascular Diseases1
  • Neurocognitive Disorders1
  • Covid191

Activity Timeline